Emerging families of biomarkers for coronary artery disease: inflammatory mediators

Yayan, Josef

doi:10.2147/vhrm.s45704

Cited by 50 publications

(32 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Из-за усугубления тяжести и роста заболеваемости во всех возрастных группах необходимо обновлять биомаркеры для ранней оценки ишемической болезни сердца пациентов. Однако есть важные исследования, которые позволяют заподо-зрить или обнаружить данную патологию: медиаторы воспаления [11], спектральный анализ электрокардио-графии, статус витамина D и кардиометаболические нарушения [12], КТ-коронароангиография [13]. Это одни из самых достоверных видов исследований, которые могут оценить состояние коронарных артерий.…”

Section: прогнозирование заболеваний пациента на основе анализа генетunclassified

Personalized Medicine in Cardiology: State, Problems and Prospects

2017

View full text Add to dashboard Cite

ФАРМАКОГЕНЕТИКАВозможность владеть генетической информацией позволила начать внедрение персонализированной медицины в клиническую практику. Генетические иссле-дования начали показывать, что некоторые лекарства в определенных условиях очень эффективны для одних пациентов и неэффективны, а иногда даже опасны -для других. Поэтому на стыке фармакологии и генетики воз-никла фармакогенетика -наука, изучающая роль генети-ческих факторов в формировании фармакологического ответа организма человека на лекарственное средство [1]. Это может дать возможность врачу персонализиро-ванно выбрать как само лекарство, так и дозу у конкрет-ного больного и обеспечить максимальную эффектив-ность и безопасность препарата.Роль наследственности в формировании индивиду-ального ответа на лекарственные средства была известна давно, понимание механизмов влияния гене-тических факторов на эффективность и безопасность фармакотерапии стало возможным лишь с развитием методов молекулярной биологии и реализацией меж-дународной программы «Геном человека». Последние данные, имеющиеся о строении генома человека, явно показывают, что существует множество вариаций генов, которые объясняют различия в абсорбции пре-парата, распределении, метаболизме, выведении и в итоге ответную реакцию организма на фармацевтиче-ский препарат. Такие предварительные успехи дали понять, что подобное исследование позволит получить такую медицину, которая окажется и индивидуальной, и точной. Personalized medicine appeared about three decades ago. Even then many scientists, researchers, doctors were interested into it. However, only after the full opening of the human genome in 2001, personalized medicine could to give the opportunity for some pathologies (oncology, rheumatology, cardiology) to choose the most effective treatment with minimal adverse drug reactions for a specific patient. The opportunity to own genetic information gives the chance to suspect, to predict, to expect the onset of the disease. Personalized medicine is able in some cases to say exactly whether the drug can work for the patient, moving us to «treat not a disease, but the patient.» But doctors to this day when determining risk factors focus on individual characteristics of the patient, such as age, gender, body weight, co-morbidities, and based on that prescribe medications, correct dose and in case of ineffectiveness change the treatment regimen. Apparently they don't believe in personalized medicine, afraid of it and I don't want to associate with it, because as many think on the basis of their experience and knowledge they can decide which drug and what dose to prescribe. Also, there are a number of reasons related to privacy, security, problem of training, which will soon need to be addressed.

show abstract

Section: прогнозирование заболеваний пациента на основе анализа генетunclassified

Personalized Medicine in Cardiology: State, Problems and Prospects

2017

View full text Add to dashboard Cite

show abstract

“…Inflammation is considered essential to the initiation, development, and progression of atherosclerosis [3].…”

Section: Introductionmentioning

confidence: 99%

“…Interleukin-6, a crucial cytokine for leukocyte and endothelial cell activation and the hepatic promoter for CRP generation, [10] in addition to more than 40 inflammatory biomarkers have been found to be useful for detecting coronary artery disease and prognosis [3].…”

Section: Introductionmentioning

confidence: 99%

Antiplatelet agents: Is twice a day a better strategy?

Arazi¹,

Badimón²

2017

Med Clin Arch

View full text Add to dashboard Cite

show abstract

“…Inflammatory markers are not specific for ACS, and any coexisting chronic disease could modify the basal body inflammatory level, resulting in very low specificity. 135 Because of these characteristics, all these markers of inflammation showed no added value in early diagnosis of MI. On the other hand, because of their sensitivity these markers have been proposed as prognostic and evolution-monitoring markers.…”

mentioning

confidence: 99%

Biomarkers in the prediction and management of acute coronary syndromes: current perspectives

Gilardi¹,

Iacomini²,

Marsiliani³

et al. 2014

RRCC

View full text Add to dashboard Cite

A large branch of research has focused on the search for biomarkers for early detection of myocardial cell injuries. Most of these studies have evaluated patients presenting to the emergency department, underlining the need for an ideal biomarker for rapid recognition of acute coronary syndrome (ACS). In the recent past, diagnosis of ACS in the emergency department has been based mostly on clinical information and electrocardiographic findings, and markers of generic cell damage have been used to support clinical suspicion. Over the last few years, the role of markers has taken up increasingly more space in non-life-threatening conditions, confining the clinical examination of the patient to the mere waiting for results of blood tests after the electrocardiograph. Currently, the biomarkers most widely used for the diagnosis of ACS are cardiac troponins. Since their introduction into clinical practice, several generations of commercial cardiac troponin assays have been validated in analytical and clinical trials. Development of newer high-sensitivity assays seems to have improved the value of cardiac troponin as both a diagnostic and risk indicator. Several other biomarkers of ACS apart from cardiac troponin have been investigated, but most still require validation in further studies. Among these, pregnancy-associated plasma protein-A, ischemia-modified albumin, and heart-type fatty acid binding protein seem to be the most promising markers under investigation for their possible usefulness in the emergency department setting for early diagnosis of ACS. In conclusion, a multimarker approach could be the future of research. In this review, we highlight the old and new markers, especially the most studied and widely used in clinical practice in recent years, particularly those that can help the clinician to make a rapid and confident diagnosis of ACS.

show abstract

Emerging families of biomarkers for coronary artery disease: inflammatory mediators

Cited by 50 publications

References 106 publications

Personalized Medicine in Cardiology: State, Problems and Prospects

Personalized Medicine in Cardiology: State, Problems and Prospects

Antiplatelet agents: Is twice a day a better strategy?

Biomarkers in the prediction and management of acute coronary syndromes: current perspectives

Contact Info

Product

Resources

About